NEW YORK, March 5, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Moments ago, Analysts Review released new research updates concerning several important developing situations including ARCA biopharma (NASDAQ: ABIO), BG Medicine (NASDAQ: BGMD), Celldex (NASDAQ: CLDX), IDEXX (NASDAQ: IDXX), and ImmuCell (NASDAQ: ICCC). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA(R) research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

ABIO Research Report: ( http://get.analystsreview.com/pdf/?c=ARCA%20biopharma&d=05-Mar-2015&s=ABIO ),

BGMD Research Report: ( http://get.analystsreview.com/pdf/?c=BG%20Medicine&d=05-Mar-2015&s=BGMD ),

CLDX Research Report: ( http://get.analystsreview.com/pdf/?c=Celldex&d=05-Mar-2015&s=CLDX ),

IDXX Research Report: ( http://get.analystsreview.com/pdf/?c=IDEXX&d=05-Mar-2015&s=IDXX ),

ICCC Research Report: ( http://get.analystsreview.com/pdf/?c=ImmuCell&d=05-Mar-2015&s=ICCC ).

============

--

Analyst Update: Orphan Drug Designation, Regulatory Updates, Quarterly Results, andPromotions

Reviewed by: Rohit Tuli, CFA(R)

The U.S. indices fell for a second straight day as investors eye private-sector employment gains and await other jobs data. A pre-opening bell report from payroll processor ADP, showed that private employers hired 212,000 [http://www.usatoday.com/story/money/business/2015/03/04/adp-national-employment-survey-february/24325467 ] workers in February, slightly below the 218,000 new jobs economists were expecting. The S&P 500 was down 9.25 points, or 0.44%, to 2,098.53 while the Dow Jones Industrial Average shed 106.47 points, or 0.58%, to 18,096.90, and Nasdaq closed 12.76 points or 0.26% lower to end the session at 4,967.14. European stocks closed higher, with export-oriented stocks getting a boost following a sharp decline in the euro to an 11-1/2-year low against the dollar after the Institute for Supply Management said its services index rose to 56.9 in February against 56.5 predicted in a Reuters poll. The Euro STOXX 50 ended the day 0.97% higher to 3,583.44 while CAC 40 gained 0.99%, to close at 4,917.35. Mainland China share market closed higher in volatile trade after the HSBC Markit survey showed activity in China's service sector grew modestly in February. Japanese share market ended down, due to strengthening of yen against dollar and taking weak cues from Wall Street overnight.

ARCA biopharma, Inc (ARCA biopharma) announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted orphan drug designation to rNAPc2, as a potential treatment of viral hemorrhagic fever post-exposure to Ebola virus.

The developer of the BGM Galectin-3(R) Test BG Medicine, Inc. (BG Medicine) has received a favorable decision from the Listing Qualifications Department (the "Staff") of The NASDAQ Stock Market LLC ("NASDAQ"), which granted the Company's request for continued listing on NASDAQ, pursuant to an extension within which to evidence compliance with NASDAQ Listing Rule 5550 (b) (the "Rule").

Celldex Therapeutics, Inc. (Celldex) announced its Q4 2014 financial results. Total revenue for the quarter increased to $1.5 million from $0.6 million in Q4 2013, led by its clinical trial collaboration with Bristol-Myers Squibb Company and the Company's' Rockefeller University services agreement.

IDEXX Laboratories, Inc. (IDEXX) announced its Q4 and full-year 2014 results. Company achieved normalized organic revenue growth of 9% for the quarter and 10% for the full year, supported by 11.5% normalized organic growth in CAG Diagnostics recurring revenues in Q4 and 11.4% for the full year. The Company also updated its guidance for 2015.

ImmuCell Corporation (ImmuCell) announced that its Director of Sales and Marketing Bobbi Jo Brockmann (Kunde) was promoted to Vice President of Sales and Marketing. Ms. Brockmann joined ImmuCell in 2010 and has been overseeing the sales and marketing of First Defense(R) and related product line extensions.

--

About Analysts Review

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA(R). An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review